These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38665375)

  • 1. Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
    Li P; Wang L; Tang Z; Wang Y; Liu Z; Ge W; Huang Y
    Front Pediatr; 2024; 12():1371322. PubMed ID: 38665375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
    Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
    Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
    Yerushalmy-Feler A; Pujol-Muncunill G; Martin-de-Carpi J; Kolho KL; Levine A; Olbjørn C; Granot M; Bramuzzo M; Rolandsdotter H; Mouratidou N; Hradsky O; Scarallo L; Matar M; Rimon RM; Rinawi F; Shalem T; Najajra H; de Meij T; Aloi M; Rodríguez-Belvís MV; Alvisi P; Schneider AM; van Rheenen P; Navas-López VM; Kiparissi F; Barrio J; Turner D; Cohen S
    J Pediatr Gastroenterol Nutr; 2022 Dec; 75(6):717-723. PubMed ID: 36084231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
    Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
    J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P066 Real-World Experience of Ustekinumab in Crohn's Disease Patients With Prior Anti-TNF Therapy at a Tertiary Care Hospital.
    Tripathi K; Groudan K; Chalhoub J; Yedla A; Singhania R
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17. PubMed ID: 37461983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study.
    Lee CK; Moon W; Chun J; Kim ES; Kim HW; Yoon H; Kim HS; Lee YJ; Choi CH; Jung Y; Park SC; Song GA; Lee JH; Jung ES; Kim Y; Jung SY; Choi JM; Ye BD
    Inflamm Bowel Dis; 2024 Aug; ():. PubMed ID: 39096895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
    Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
    Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
    Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
    Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
    J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
    Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
    [No Abstract]   [Full Text] [Related]  

  • 15. Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease.
    Kim FS; Patel PV; Stekol E; Ali S; Hamandi H; Heyman MB; Verstraete SG
    J Pediatr Gastroenterol Nutr; 2021 Nov; 73(5):610-614. PubMed ID: 34415711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.
    Argüelles-Arias F; Rodriguez González FJ; González Antuña J; Castro Laria L; Gutiérrez Martinez F; Alcaín Martinez G; Maldonado Pérez B; Camargo Camero R; Martos Van Dussen JV; Fernández Castañer A; Valdés Delgado T
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 39082955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study.
    Oh K; Hong HS; Ham NS; Lee J; Park SH; Yang SK; Yoon H; Kim YS; Choi CH; Ye BD;
    Intest Res; 2023 Jan; 21(1):137-147. PubMed ID: 36751044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
    Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
    Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
    [No Abstract]   [Full Text] [Related]  

  • 19. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
    Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
    Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.
    Takeuchi I; Arai K; Kyodo R; Sato T; Tokita K; Hirano Y; Shimizu H
    J Gastroenterol Hepatol; 2021 Jan; 36(1):125-130. PubMed ID: 32497325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.